|| Print ||
|Articles - February 2013|
|Monday, January 28, 2013|
Page 3 of 4
John Bial, president and CEO of biotech firm Yecuris Corporation in Portland, thinks first to file means “people will have to be a lot more careful in their conversations,” and says it’s seldom clear in collaboration when a patentable idea has presented itself. “You never know until you’re done if it’s going to generate anything useful.”
“People are naive,” he adds. “They don’t get the right kinds of confidentiality agreements in place and they get scooped. And now it will be worse.” Yecuris has two patents pending for mice bioengineered to contain human livers and immune systems, which sell for $1,500 to $3,500 per mouse as research subjects for drug metabolism, toxicity and a host of infectious diseases. The company also has a patent pending on a rat version of its technology and licenses two patents to enable operability of the models.
Bial anticipates a five-year wait on patents. In the biotech field, slower patent examination is the norm, along with extended waits for FDA approval, so the 20-year monopoly on a product is often cut in half or worse. Bial hopes the reforms will speed up patents and reduce litigation. He knows of one infringement suit that lasted 10 years. “It cost time and money on both sides. I’m not sure that anyone won.”
Wednesday, August 06, 2014
BY LINDA BAKER | OB EDITOR
Portland startup Green Endeavor strikes gold, inking a partnership with Underwriters Laboratories, an Illinois-based consulting and certification company with offices in 46 countries.
Monday, August 25, 2014
BY JASON NORRIS | OB GUEST BLOGGER
Ferguson Wellman’s investment views on the economy and capital markets.
Tuesday, August 19, 2014
BY TOM COX | OB BLOGGER
Tom Cox interviews Steve Balzac, author of "Organizational Psychology for Managers."
Wednesday, August 27, 2014
Tom Cox interviews Pete Friedes, author of "The 2R Manager," about becoming a Best Boss.
Tuesday, August 26, 2014
Strong public schools shore up the economy, survey respondents say. But local schools demonstrate lackluster performance.
Thursday, August 28, 2014
OB Research Editor Kim Moore shares some pointers about the 100 Best Companies to Work For survey.
Tuesday, July 08, 2014
BY LINDA BAKER | OB EDITOR
The New Yorker recently published a sharply worded critique of “disruptive innovation,” one of the most widely cited theories in the business world today. The article raises questions about the descriptive value of disruption and innovation — whether the terms are mere buzzwords or actually explain today's extraordinarily complex and fast changing business environment.
Update: We caught up with Portland's Thomas Thurston, who shared his data driven take on the disruption controversy.
|The Private 150: Bigger But Leaner|
|The Perfect Food|
|Powerlist: Staffing Firms|
|Taxis Uber Alles?|
|Halliburton to pay $1.1B to settle lawsuits|
|U.S. eating habits improve, except among poor|
|Google tests drone deliveries|
|Abercrombie to remove logos from most clothing|
|FBI investigates JPMorgan 'cyber-attack'|
|GoPro launches camera dog harnesses|
|Snapchat now worth $10B|
First Call Resolution targets employee well-being and client satisfaction.
How six leading foundations are working together for a better Oregon.
Vigilant enters a New Year with a new president.
Lane Powell Shareholder William T. Patton has been appointed to the board of directors for Cascade AIDS Project, an organization that provides educational services and outreach to thousands of Oregonians living with HIV/AIDS.
Fifty-one Lane Powell lawyers were recently selected by their peers for inclusion in The Best Lawyers in America® (Best Lawyers) 2015; of those selected, 23 lawyers are from the Firm’s office in Portland, Oregon.
Barran Liebman is proud to announce that Andrew Schpak, a Partner of the firm, has been named Chair of the American Bar Association’s Young Lawyers Division for the 2014-2015 bar year.